We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

1 hedge funds and large institutions have $159K invested in Array Biopharma Inc in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 316 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 318 → 1 (-317)

100% less funds holding in top 10

Funds holding in top 10: 28 → 0 (-28)

100% less capital invested

Capital invested by funds: $10.5B → $159K (-$10.5B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 316

Holders
1
Holders Change
-317
Holders Change %
-99.69%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-28
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
316
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$943M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$890M
3
BlackRock
BlackRock
New York
-$824M
4
RG
Redmile Group
California
-$405M
5
FCM
Farallon Capital Management
California
-$394M
Name Holding Trade Value Shares
Change 		Change in
Stake
AAM
276
Aureus Asset Management
Massachusetts
– -$208K -4,500 Closed
PA
277
Profund Advisors
Maryland
– -$205K -4,430 Closed
SCA
278
Spearhead Capital Advisors
Florida
– -$202K -4,363 Closed
AG
279
Advisor Group
Arizona
– -$150K -3,229 Closed
OAM
280
Oppenheimer Asset Management
New York
– -$149K -3,217 Closed
LTFS
281
Ladenburg Thalmann Financial Services
Florida
– -$142K -3,075 Closed
GT
282
Glenmede Trust
Pennsylvania
– -$138 -3,000 Closed
Rockefeller Capital Management
283
Rockefeller Capital Management
New York
– -$138K -2,979 Closed
QT
284
Quantbot Technologies
New York
– -$134K -2,900 Closed
QT
285
Quantamental Technologies
New York
– -$117K -2,534 Closed
Walleye Capital
286
Walleye Capital
New York
– -$116K -2,500 Closed
Daiwa Securities Group
287
Daiwa Securities Group
Japan
– -$64K -1,388 Closed
NFG
288
Next Financial Group
Texas
– -$60K -1,300 Closed
HFM
289
Harvest Fund Management
China
– -$60K -1,287 Closed
EI
290
Ellevest Inc
New York
– -$51K -1,101 Closed
QCG
291
Quadrant Capital Group
Ohio
– -$48K -1,040 Closed
CL
292
CSS LLC
Illinois
– -$42K -900 Closed
Federated Hermes
293
Federated Hermes
Pennsylvania
– -$39K -839 Closed
AOWM
294
Alpha Omega Wealth Management
Virginia
– -$31K -661 Closed
AW
295
Alpha Windward
Massachusetts
– -$28K -581 Closed
SFSIG
296
San Francisco Sentry Investment Group
California
– -$26K -574 Closed
CAW
297
Cornerstone Advisors (Washington)
Washington
– -$25K -545 Closed
JFA
298
JNBA Financial Advisors
Minnesota
– -$23K -500 Closed
PA
299
Parallel Advisors
California
– -$23K -500 Closed
CIA
300
CSat Investment Advisory
Michigan
– -$22K -475 Closed
9 10 11
12
13

ARRY Hedge Fund Activity: Q3 2019 in Review

1 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q3 2019, worth a combined $159K — down 100% from $10.5B a quarter earlier.

Sellers outnumbered buyers: 316 funds closed out of ARRY and 0 opened new positions — a net loss of 316 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $943M sold.

  • 1 institutional investor held Array Biopharma Inc (ARRY) as of Q3 2019, down from 318 in Q2 2019.
  • Funds reported $159K of Array Biopharma Inc stock for Q3 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Array Biopharma Inc positions in Q3 2019 and 316 closed out, a net change of -316 holders.
  • The largest Array Biopharma Inc seller in Q3 2019 was Vanguard Group, an estimated $943M sold.

Based on aggregated 13F filings for Q3 2019.